- Immunocore reports first quarter financial results and provides a business update
- EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
- Immunocore announces upcoming presentation and posters at ASCO 2024
- Immunocore to present at upcoming investor conferences
- Immunocore presented two posters at CROI 2024
- Immunocore to present at upcoming investor conferences
- Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
- Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
- Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
- Immunocore Prices Upsized Convertible Senior Notes Offering
More ▼
Key statistics
On Tuesday, Immunocore Holdings PLC (IMCR:NSQ) closed at 51.00, 20.82% above the 52 week low of 42.21 set on Oct 30, 2023.
52-week range
Open | 53.00 |
---|---|
High | 53.40 |
Low | 50.82 |
Bid | 49.00 |
Offer | 51.75 |
Previous close | 53.15 |
Average volume | 613.37k |
---|---|
Shares outstanding | 50.01m |
Free float | 44.13m |
P/E (TTM) | -- |
Market cap | 2.66bn USD |
EPS (TTM) | -1.13 USD |
Data delayed at least 15 minutes, as of May 21 2024 21:00 BST.
More ▼